TOCAINIDE HYDROCHLORIDE

US Previously Marketed

Details

Stereochemistry	RACEMIC
Molecular Formula	C11H16N2O.ClH
Molecular Weight	228.718
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(N)C(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=AMZACPWEJDQXGW-UHFFFAOYSA-N

InChI=1S/C11H16N2O.ClH/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12;/h4-6,9H,12H2,1-3H3,(H,13,14);1H

HIDE SMILES / InChI

Molecular Formula	C11H16N2O
Molecular Weight	192.2575
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/cons/tocainide.html
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01056 | https://www.ncbi.nlm.nih.gov/pubmed/2499645 | https://www.ncbi.nlm.nih.gov/pubmed/3107988 | https://www.ncbi.nlm.nih.gov/pubmed/2108835 | https://www.ncbi.nlm.nih.gov/pubmed/3161487

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose-dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide. The recommended initial dosage is 400 mg every 8 hours. The usual adult dosage is between 1200 and 1800 mg/day in a three-dose daily divided regimen. Doses beyond 2400 mg per day have been administered infrequently. Patients who tolerate the t.i.d. the regimen may be tried on a twice-daily regimen with careful monitoring. Tocainide commonly produces minor, transient, nervous system and gastrointestinal adverse reactions, but is otherwise generally well tolerated.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channel alpha subunit 72 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2451117	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ventricular arrhythmia 50 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2108835	Primary		Approved 8583	TONOCARD Approved Use Unknown Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
3.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3116834	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		TOCAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
11.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2127569	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	(S)-TOCAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2127569	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	R(-)-TOCAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3116834	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOCAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
17.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2127569	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	(S)-TOCAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2127569	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	R(-)-TOCAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3116834	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOCAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 2 times / day single, intravenous Dose: 250 mg, 2 times / day Route: intravenous Route: single Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	unhealthy, 34 - 75 years Health Status: unhealthy Age Group: 34 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	Disc. AE: Hypotension... Other AEs: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Hypotension (3 patients) Other AEs: Nausea (1 patient) Vomiting (1 patient) Junctional rhythm (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/6439023
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	Disc. AE: Ataxia, Tremor... AEs leading to discontinuation/dose reduction: Ataxia (8 patients) Tremor (8 patients) Dizzy (8 patients) Rash (4 patients) Diarrhea (1 patient) Nausea (1 patient) Vomiting (1 patient) Anorexia (1 patient) Congestive heart failure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3931448

AEs

AE	Significance	Dose	Population
Junctional rhythm	1 patient	250 mg 2 times / day single, intravenous Dose: 250 mg, 2 times / day Route: intravenous Route: single Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	unhealthy, 34 - 75 years Health Status: unhealthy Age Group: 34 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6439023
Nausea	1 patient	250 mg 2 times / day single, intravenous Dose: 250 mg, 2 times / day Route: intravenous Route: single Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	unhealthy, 34 - 75 years Health Status: unhealthy Age Group: 34 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6439023
Vomiting	1 patient	250 mg 2 times / day single, intravenous Dose: 250 mg, 2 times / day Route: intravenous Route: single Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	unhealthy, 34 - 75 years Health Status: unhealthy Age Group: 34 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6439023
Hypotension	3 patients Disc. AE	250 mg 2 times / day single, intravenous Dose: 250 mg, 2 times / day Route: intravenous Route: single Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6439023	unhealthy, 34 - 75 years Health Status: unhealthy Age Group: 34 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6439023
Anorexia	1 patient Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Congestive heart failure	1 patient Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Diarrhea	1 patient Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Nausea	1 patient Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Vomiting	1 patient Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Rash	4 patients Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Ataxia	8 patients Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Dizzy	8 patients Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448
Tremor	8 patients Disc. AE	600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3931448	unhealthy, 59 years (range: 28-83 years) Health Status: unhealthy Age Group: 59 years (range: 28-83 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3931448

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 132 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10215663/	yes [Inhibition 2000 uM]
CYP1A1 272	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8689940/	yes [Ki 12400 uM]

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	35891-93-1	https://www.alfa-chemistry.com/cas_35891-93-1.htm
Ambinter	Amb22336892	http://www.ambinter.com/reference/22336892
Aurora Fine Chemicals LLC	A17.901.147	http://online.aurorafinechemicals.com/info?ID=A17.901.147
Avantor Inc	101094-176	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-176
Chem Scene	CS-0013838	http://www.chemscene.com/71395-14-7.html
ChemMol	99074262	http://www.chemmol.com/chemmol/99074262.html
Chemspace	CSSS00015314419	https://chem-space.com/CSSS00015314419
Clearsynth	CS-T-87276	https://www.clearsynth.com/en/CST87276.html
LGC Standards	LGCFOR3323.00	https://www.lgcstandards.com/US/en/p/LGCFOR3323.00
MedChem Express	HY-B1798A	https://www.medchemexpress.com/tocainide-hydrochloride.html
MolPort	MolPort-046-647-173	https://www.molport.com/shop/molecule-link/MolPort-046-647-173
MuseChem	R062387	https://www.musechem.com/product/R062387.html
Sigma-Aldrich	1667552_USP	https://www.sigmaaldrich.com/catalog/product/usp/1667552?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	T0202_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/t0202?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral

PubMed

Title	Date	PubMed
Tocainide analogues binding to human serum albumin: a HPLAC and circular dichroism study.	2010-10-10	20359840
Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models.	2010-08-25	20580661
Sodium channelopathies of skeletal muscle result from gain or loss of function.	2010-07	20237798
Update on methodologies available for ciguatoxin determination: perspectives to confront the onset of ciguatera fish poisoning in Europe.	2010-06-14	20631873
2D- and 3D-QSAR of tocainide and mexiletine analogues acting as Na(v)1.4 channel blockers.	2009-04	19027197
Tinnitus: characteristics, causes, mechanisms, and treatments.	2009-03	19513328
Liquid chromatographic direct resolution of tocainide and its analogs on a (3,3'-diphenyl-1,1'-binaphthyl)-20-crown-6-based chiral stationary phase containing residual silanol protecting n-octyl groups.	2009-01	18506839
Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents.	2008-11	18342401
Drug therapy considerations in arrhythmias in children.	2008-08-01	18679519
Preparation of two new liquid chromatographic chiral stationary phases based on diastereomeric chiral crown ethers incorporating two different chiral units and their applications.	2008-05-16	18037425
Cyclic metabolites: chemical and biological considerations.	2008-02	18288959
[Eulenburg's paramyotonia congenita].	2007-11	18033047
Synthesis and biological evaluation of chiral alpha-aminoanilides with central antinociceptive activity.	2007-04-19	17373780
Non-antiepileptic drugs for trigeminal neuralgia.	2006-07-19	16856027
Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods.	2006-03	16290201
Robust randomised control trials needed for drug treatments for trigeminal neuralgia.	2006	17187047
Chiral separations on multichannel microfluidic chips.	2005-12	16278920
Systemic administration of local anesthetic agents to relieve neuropathic pain.	2005-10-19	16235318
Ventricular tachycardia induced by biventricular pacing in patient with severe ischemic cardiomyopathy.	2005-06	15946367
[Pharmacological treatment of trigeminal neuralgia: systematic review and metanalysis.].	2004-12	19471799
Synthesis, structure and pharmacology of acyl-2,6-xylidines.	2004-10-16	15481248
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.	2004-07	15210163
High-speed chiral separations on a microchip with UV detection.	2003-09	14518050
Pulmonary fibrosis associated with tocainide: report of a case with literature review.	1990-02	2137316
Congestive heart failure induced by six of the newer antiarrhythmic drugs.	1989-11-01	2509529
Sinoatrial block due to tocainide.	1989-10	2508453
Tocainide-induced aplastic anemia.	1989-01	2497588
Possible proarrhythmic effects of tocainide in dilated cardiomyopathy.	1988-07	2457881
Effect on the seizure threshold in dogs of tocainide/lidocaine administration.	1987-07	3109286
Tocainide-induced reversible agranulocytosis and anemia.	1987-03	3103562
Tocainide-induced granulomatous hepatitis.	1986-06-27	3086580
Successful treatment with tocainide of recessive generalized congenital myotonia.	1986-05	3087270
Efficacy and safety of oral tocainide in refractory ventricular arrhythmia: a preliminary report on an open label study.	1986-04	2424347
Aplastic anemia due to tocainide.	1986-02-27	3080682
A seizure induced by concurrent lidocaine-tocainide therapy--is it just a case of additive toxicity?	1986-01	3080299
A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus.	1985-04	3928215
Confusion and paranoia associated with oral tocainide.	1985-01	3921948
Exacerbation of ventricular tachycardia by tocainide.	1985-01	3917881
[Analysis and toxicity of the anti-arrhythmia agent tocainide].	1985	3931622
Facilitation of ventricular tachyarrhythmia induction by isoproterenol.	1984-10-01	6486026
Paranoid psychoses induced by tocainide.	1984-03-31	6423157
Paranoid psychosis induced by tocainide.	1984-02-25	6421396
Heart failure and hepatitis in a patient taking tocainide.	1984-01	6420353
Antiarrhythmic effects of tocainide and lidocaine in dogs.	1983-08	6414246
Tocainide. A review of its pharmacological properties and therapeutic efficacy.	1983-08	6411445
Nodal bradycardia induced by tocainide.	1983-04	6408628
Severe paranoia with concomitant tocainide and propranolol therapy.	1982-03-01	6821034
Tocainide-induced ventricular fibrillation.	1981-04	6782848
New drugs for treating cardiac arrhythmias.	1981-01	6780988
Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents.	1980-12	6778190

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 400 mg orally every 8 hours. Maintenance dose: 1200-1800 mg/day in 3 divided doses.

Route of Administration: Oral

In Vitro Use Guide

Cardiac myocytes were isolated from adult male Sprague-Dawley rats. Myocytes (6 x 10^5) in 50 mkl of incubation buffer were incubated with 1.3 mkM sea anemone toxin II, 13 nM [3H] BTXB (50 Ci/mmol), and 0.13 mM tetrodotoxin for 45-60 mm at 37C. Tetrodotoxin was added to prevent depolarization induced by sodium influx; without tetrodotoxin, no specific binding is observed. Various concentrations of tocainide enantiomers were included in the incubations. Assays were done in parallel with tubes containing 0.2 mM aconitine to define nonspecific binding. Concentration-response curves for both stereoisomers were performed on common preparations of cells and toxins. Reactions were terminated by adding 10 ml of KHS buffer (Krebs-Henseleit-BSA; 127 mM NaCl, 2.33 mM KC1, 1.30 mM KH2PO4, 1.23 mM MgSO4, 25 mM NaHCO3, 10 mM glucose, 50 mkM CaCl2, 1% BSA) equilibrated with 95% 02/5% CO2 and incubated at 3C for 1 min, then filtered through a Whatman GF-C 24-mm filter and washed five times with 5 ml of rinse buffer (25 mM Tris-Cl, pH 7.4, 130 mM NaCl, 5.5 mM KC1, 0.8 mM MgSO4, 5.5 mM glucose, 50 mkM CaCl2.) The filters were then dried and counted in Econofluor scintillation fluid. The retained radioactivity represents [3H]BTXB bound to the myocyte.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:12:14 GMT 2025` Edited by `admin` on `Mon Mar 31 19:12:14 GMT 2025`
Record UNII	2K7I38CKN5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOCAINIDE HYDROCHLORIDE

Common Name

English

TOCAINIDE (±)-FORM HYDROCHLORIDE

Preferred Name

English

PROPANAMIDE, 2-AMINO-N-(2,6-DIMETHYLPHENYL)-, MONOHYDROCHLORIDE

Common Name

English

TOCAINIDE HCL

Common Name

English

Tocainide hydrochloride [WHO-DD]

Common Name

English

2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE MONOHYDROCHLORIDE

Systematic Name

English

TOCAINIDE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

TOCAINIDE MONOHYDROCHLORIDE

Common Name

English

TOCAINIDE HYDROCHLORIDE [VANDF]

Common Name

English

TOCAINIDE (±)-FORM HYDROCHLORIDE [MI]

Common Name

English

TOCAINIDE HYDROCHLORIDE [MART.]

Common Name

English

TOCAINIDE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47793